REGENXBIO reports Q3 2026 results, confirms Duchenne BLA and wet AMD data timelines
The company said it remains on track for a Q1 2027 RGX-202 BLA submission and expects topline sura-vec wet AMD data in Q4 2026, while cash stood at $251.0 million.
SEC filing